trial
as of 2026-07-01Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
NCTId NCT00074477
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
250 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-10
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Johnson & JohnsonLead Sponsor
Sites
0 total
Facts & assertions
3 sourced
Enrollment
250
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication